Publications by authors named "Mark Hadden"

Claim this Profile
A
Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites.
Felix S Meier-Stephenson, Vanessa C Meier-Stephenson, Michael D Carter, Autumn R Meek, Yanfei Wang, Mark Hadden

Alzheimers Dement (N Y)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.
Mark Hadden, Dustin M Deering, Alan J Henderson, Matthew D Surman, Michele Luche

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydrocarboline analogs as MCH-1 antagonists.
Alan J Henderson, Dustin Deering, James F Grabowski, Mark Hadden, Xiaowu Jiang

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
Matthew D Surman, Emily E Freeman, James F Grabowski, Mark Hadden, Alan J Henderson

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Mark Hadden, Allan Goodman, Cheng Guo, Peter R Guzzo, Alan J Henderson

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
Cheng Guo, Peter R Guzzo, Mark Hadden, Bruce J Sargent, Larry Yet

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Jian Liu, Shuwen He, Tianying Jian, Peter H Dobbelaar, Iyassu K Sebhat, Mark Hadden

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.
Shuwen He, Peter H Dobbelaar, Jian Liu, Tianying Jian, Iyassu K Sebhat, Mark Hadden

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,3-Diaminopyrazines as Rho kinase inhibitors.
Alan J Henderson, Mark Hadden, Cheng Guo, Neema Douglas, Helene Decornez

Bioorg Med Chem Lett· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
James R Corte, Tianan Fang, Donald J P Pinto, Wei Han, Zilun Hu, Mark Hadden

Bioorg Med Chem Lett· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin.
Dianne Z Hillyard, Angus J M Cameron, Alan H McIntyre, Mark H Hadden, Hilary E Marshall

Clin Exp Pharmacol Physiol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis